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Recombinant Protein Production and
Insect Cell Culture and Process
ORIGIN OF THE INVENTION
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The jointly made invention described herein was made by
employees of the United States Government and may be
manufactured and used by or for the Government of the United
States of America for governmental purposes without the
payment of any royalties thereon or therefor.
The invention described herein was also made by inventors
in the performance of work under a NASA contract with Krug
Life Sciences and a memorandum of understanding with Tulane
University and is subject to the provisions of Section 305 of
the National Aeronautics and Space Act of 1958, Public Law 85-
568 (72 Stat. 435; 42 U.S.C. 2457).
15 BACKGROUND OF THE INVENTION
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In vitro cultures of animal cells are hosts for an
increasing assortment of recombinant protein products. This
is a relatively new phenomenon, beginning in the mid 1980's.
In this short period of time, these proteins have made a
substantial contribution to the U.S. economic market. In the
pharmaceutical industry alone, biotherapies, which are
primarily recombinant proteins, generated $1.2 billion in U.S.
sales in 1991 and will grow to nearly $8.0 billion in 2001 as
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more proteins become commercially available [Thayer, A. M.,
C & EN, Feb. 25, 27 (1991)]. The market size and its capacity
for growth demonstrate the importance of recombinant protein
production to the fields of biotechnology and bioengineering.
Recombinant proteins derived from animal cells are
employed in a range of disciplines from agriculture to
medicine to basic research. During the past decade in
medicine, progress has been made in genetic engineering and
animal-cell cultivation to produce an increasing assortment of
recombinant proteins in sufficient quantities for the
development of new drug therapies. The proteins themselves
can serve as therapies, or they can be used to identify and
test chemotherapies that regulate protein function in vivo.
Recombinant tissue plasminogen activator is an example of a
protein therapy. It is given to patients with evolving
myocardial infarction to dissolve coronary thrombus and
restore blood flow to the ischemic area [Longridge, D. J.,
Follenfant, M. J., Maxwell, M. P., Ford, A. J., and Hughes B.,
Cardiovasc. Res., 24, 697 (1990)]. In clinical trials,
another protein therapy, erythropoietin, has been used to
treat anemia in patients with progressive renal failure
[Eschbach, J. W., Kelly, M. R., Haley, N. R., Abels, R. I.,
and Adamson, J. W., N. Engl. J. Med., 321, 158 (1989)] and
sickle cell disease [Goldberg, M. A., Brugnara, C., Dover, G.
J., Schapira, L., Charache, S., and Bunn, H. F., N. Engl. J.
Med., 323, 366 (1990)]. Examples of protein-regulating
chemotherapies include enalapril, an inhibitor of angiotensin-
converting enzyme, for the treatment of sickle cell disease.
[Falk, R. J., Scheinman, J., Phillips, G., Orringer, E.,
Johnson, A., and Jennette, J. C., N. Engl. J. Med., 326, 910-
915 (1992)]. A chemotherapy derived from azole regulated
cytochrome P-450 dependent testosterone biosynthesis [Bossche,
H. V., Lauwers W., Willemsens, G., Cools, W., Prog. Clin.
Biol. Res., 185A, 187 (1985)].
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At present, both procaryotes and eucaryotes are utilized
as hosts for commercial production of recombinant proteins.
The choice of one over the other is based on the structural
complexity of the protein being produced and the desired
yield. If a protein can be produced in a biologically active
form from either host, procaryotes are preferred: they grow
faster and express more protein than animal cells [Marino, M.
H., BioPharm, July/August, 18 (1989); Bebbington, C. and
Hentschel, C., Trends Biotechnol., 3, 314 (1985)]. Doubling
times are in hours rather than days. Similarly, yields are in
grams of protein per liter media rather than milligrams per
liter. Eucaryotes are chosen as hosts when procaryotes are
unable to produce functional protein [Marino, M. H., BioPharm,
July/August, 18 (1989); Bebbington, C. and Hentschel, C.,
Trends Biotechnol., 3, 314 (1985)]. This typically occurs
when the protein requires post-translational modification
(e.g., glycosylation, phosphorylation or macromolecular
assembly) to be functional. Bacteria cannot perform post-
translational modifications at all; simple eucaryotes such as
yeast do so to a limited extent; but complex eucaryotes such
as animal cells, with few exceptions, perform the entire
complement of post-translational modifications.
Commercial production of recombinant proteins from animal
cells requires that the production process be reliable,
yielding consistent amounts of product with reproducible
biological activity. Such stringency has been achieved in
vitro from animal cells cultured in a bioreactor which
provides a controlled environment for cell growth.
Several bioreactor designs have been employed in the past
for the cultivation of animal cells [Merten, O. W., Trends
Biotechnol., 5, 230 (1987); Nelson, K.L., BioPharm., February,
42 (1988); Tramper, J., Smit, D., Straatman, J., and Vlak, J.
M., Bioprocess Eng., 3, 37 (1988)]. These include a stirred-
tank reactor, a hollow-fiber reactor containing porous fiber
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bundles in which cells grow, and an airlift reactor in which
gas bubbles rise through a draft tube lifting the culture
fluid to the top of the reactor where it returns to the bottom
through the annular space between the draft tube and outer
shell of the reactor. [See Inlow et al., U.S. Pat. No.
5,024,947, entitled "Serum Free Media For the Growth on Insect
Cells and Expression of Products Thereby", issued June 18,
1991]. Bioreactors up to i0,000 liters in size are used in
industry for animal cells [Rhodes, M., Genetic Engineering
News, i0, March, 7 (1990)]. Choosing the size and type of
bioreactor for a particular process depends on a number of
factors such as market demand, cell properties and yield.
Hollow-fiber reactors are currently limited to volumes on the
order of one liter [Cracauer et al., U.S. Pat. No., 4,804,628,
entitled "Hollow Fiber Cell Culture Device and Method of
Operation" issued Feb. 14, 1989; Nelson, K.L., BioPharm.,
March, 34 (1988)]. Airlift reactors can not readily keep
microcarrier cultures (attachment-dependent cells growing
bound to beads that are typically I00 _m in diameter) well
mixed [Merten, O. W., Trends Biotechnol., 5, 230 (1987)]. The
stirred-tank reactor is the system of choice for many
companies because of its flexibility: it can support the
growth of both suspension and anchorage-dependent cells, can
be operated in different feed modes, and can be scaled up to
very large volumes (I0,000 liters) [Nelson, K.L., BioPharm.,
March, 34 (1988); Nelson, K.L., BioPharm., February, 42
(1988) ].
In bioreactors, mixing is essential for cell
proliferation: it supplies cells with nutrients and oxygen,
maintains a homogenous environment throughout the reactor, and
prevents cells from settling. But in conventional
bioreactors, mixing can also cause cell damage from
sufficiently large hydrodynamic forces. In a stirred tank,
for example, cell damage has been attributed to two mixing
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phenomena: bulk-fluid turbulence and gas/liquid interfaces
[O'Connor, K. C. and Papoutsakis, E. T., Biotechnol. Tech., 6,
323 (1992); Kunas, K. T. and Papoutsakis, E. T., Biotechnol.
Bioeng., 36, 476-483 (1990)]. Typically, these interfaces
arise during cultivation as a result of sparging, vortex
formation, turbulent eddies, fluid-wall shear gradients and
surface oxygenation. Cell damage from bulk-liquid turbulence
has been correlated to the ratio of the Kolmogorov-scale eddy
size to bead diameter for microcarrier cultures [Cherry, R. S.
and Papoutsakis, E. T., Bioprocess Eng., I, 29-41 (1986);
Croughan, M. S., Hamel, J. F., and Wang, D. I. C., Biotechnol.
Bioeng., 29, 130-141 (1987)] and cell diameter for suspension
cultures [Kunas, K. T. and Papoutsakis, E. T., Biotechnol.
Bioeng., 36, 476-483 (1990); McQueen, A., Meilhoc, E., and
Bailey, J. E., Biotechnol. Letters, 9, 831 (1987)]. Damage
initiates as the ratio approaches unity and intensifies at
lower values. It has been proposed that eddies of the same
size or smaller than cell particles (microcarrier beads or
individual cells) cause high shear stresses on the cell
surface, interparticle collisions and reactor-particle
collisions [Cherry, R. S. and Papoutsakis, E. T., Bioprocess
Eng., i, 29-41 (1986)]. For larger eddies, shearing and
collisions are minimized as cell particles move in eddy
streamlines.
Because animal cells are not enclosed in a cell wall like
bacteria, they are susceptible to hydrodynamic forces within
a bioreactor. Agitation, shear and other hydrodynamic
phenomena have a profound effect on cell morphology and
physiology which can result in cell damage and death. From a
morphological perspective, hydrodynamic forces alter cell
shape, adhesion, membrane integrity and spreading [O'Rear, E.
A., Udden, M. M., McIntire, L. V., and Lynch E. C., Biochim.
Biophys. Acta, 691, 274 (1982); Lawrence, M. B., McIntire, L.
V., and Eskin, S. G., Blood, 70, 1284 (1987); Ives, C. L.,
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Eskin, S. G., and McIntire, L. V., In Vitro Cell. Dev. Biol.
22, 500 (1986)]. These morphological changes are accompanied
by and related to physiological changes in DNA synthesis, mRNA
synthesis and cytoskeletal rearrangement to name a few
[O'Connor, K. C. and Papoutsakis, E. T., Biotechnol. Tech., 6,
323 (1992); Diamond, S. L., Sharefkin, J. B., Dieffenbach, C.,
Frasier-Scott, D., McIntire, L. V., and Eskin, S. G., J. Cell.
Physiol., 143, 364-371 (1990); Sato, M., Levesque, M. J., and
Nerem, R. M., Arteriosclerosis, 7, 276 (1987)]. There are
several mechanisms by which these hydrodynamic effects can
cause cell death, including lysis from loss of membrane
integrity, detachment of anchorage-dependent cells from
surfaces, and reduced metabolic activity [O'Connor, K. C. and
Papoutsakis, E. T., Biotechnol. Tech., 6, 323 (1992);
Croughan, M. S., Hamel, J. F., and Wang, D. I. C., Biotechnol.
Bioeng., 33, 731-744 (1989); Petersen, J. F., McIntire, L. V.,
and Papoutsakis, E. T., J. Biotechnol., 7, 229 (1988)].
Insect cells are distinctly different from animal cells.
Very little is known about insect cell metabolism. There is
a relatively small body of literature on the subject. Insects
and vertebrate animals are classified in totally different
phylogenetic systems. Consequently, insect cells have
undergone a metabolic evolution that was completely
independent compared to animal cell metabolic evolution.
Insects have a unique life cycle and, as such, have distinct
cellular properties. One of these is the lack of
intracellular plasminogen activators in insect cells which are
present in vertebrate cells. These differences were
highlighted when investigators began to express recombinant
intact human plasminogen in Sf9 cells after unsUccessful
attempts in vertebrate cells. The metabolic differences that
enabled expression are unknown. [Whitefleet-Smith, J., Rosen,
E., McLinden, J., Ploplis, V. A., Fraser, M. J., Tomlinson, J.
E., McLean, J. W., and Castellino, F. J., Arch. Biochem.
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Biophys., 271, 390 (1989)]. In the latter, plasminogen is
rapidly converted by the activators to plasmin. Other
differences include high expression levels of protein products
ranging from 1 to greater than 500 mg/liter [Marino, M. H.,
BioPharm, July/August, 18 (1989)] and ease at which DNA can be
cloned into the cells [Fraser, M. J., In Vitro Cell. Dev.
Biol., 25, 225 (1989); Summers, M. D. and Smith, G. E., A
Manual of Methods for Baculovirus Vectors and Insect Cell
Culture Procedures, Texas Agricultural Experiment Station
Bulletin No. 1555 (Texas A & M University, College Station,
Texas, 1988)], both of which make insect cells exceptional
hosts for protein production.
Cultivation of insect cells is difficult particularly on
a large scale or at a high cell density since they are more
sensitive to hydrodynamic forces in a bioreactor [Wu, J.,
King, G., Daugulis, A. J., Faulkner, P., Bone, D. H., and
Goosen, M. F. A., Appl. Microbiol. Biotechnol., 32, 249
(1989); Tramper, J., Williams, J. B., and Joustra, D., Enzyme
Microb. Techno., 8, 33 (1986)] and have a greater oxygen
uptake rate than most vertebrate cells [Maiorella, B., Inlow,
D., Shauger, A., and Harano, D., Bio/Technology, 6, 1406
(1988)]. The oxygen uptake rate has been calculated to be 4
x I0 -I0 mmole cell -I hr -I for Trichoplusia ni cells [Maiorella,
B., Inlow, D., Shauger, A., and Harano, D., Bio/Technology, 6,
1406 (1988)] as compared to 0.i to 2 x i0 -I0 mmole cell -I hr -I
for typical vertebrate cells [Nelson, K.L., BioPharm., March,
34 (1988)]. The sensitivity to hydrodynamic forces is so
severe that growth of a Lepidopteran cell line, the fall
armyworm ovary Spodoptera frugiperda (Sf9), is completely
inhibited in bench-scale sparged stirred tanks or airlift
bioreactors unless surfactant is added to protect the cell
membrane [Murhammer, D. W. and Goochee, C. F., Biotechnol.
Prog., 6, 391 (1990)]. The combination of enhanced
respiration and hydrodynamic sensitivity places severe
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constraints on cell oxygenation: sufficient oxygen must be
transported to the insect cells for respiration without
inducing hydrodynamic damage to the cells. Conventional
methods of oxygenation, such as sparging, supply sufficient
oxygen but do so by increasing mixing of growth medium and gas
flow rate, resulting in cell destruction from hydrodynamic
forces in the medium and at the gas/liquid interface.
Developing a bioreactor environment which achieves favorable
conditions for growth through a reduction in hydrodynamic
forces is a topic of much interest today. One of the features
of this invention is the specific non-animal cell culture
processes stemming from shear reduction and the discovery of
novel in vitro metabolism.
Much of the cultivation and production research on insect
cells has been performed with Sf9 cells [Wu, J., King, G.,
Daugulis, A. J., Faulkner, P., Bone, D. H., and Goosen, M. F.
A., AppI. Microbiol. Biotechnol., 32, 249 (1989); Maiorella,
B., Inlow, D., Shauger, A., and Harano, D., Bio/Technology, 6,
1406 (1988); Godwin, G., Belisle, B., De Giovanni, A., Kohler,
J., Gong, T., and Wojchowski, D., In Vitro, 25, 17a (1989)].
This cell line is frequently chosen because it grows more
robustly than other insect cells, is an immortal cell line,
can be adapted from attachment-dependent to attachment-
independent growth, is an exceptional host for recombinant
protein production as described in the following paragraph,
can grow in serum-free media and is commercially available
[Fraser, M. J., In Vitro Cell. Dev. Biol., 25, 225 (1989); Wu,
J., King, G., Daugulis, A. J., Faulkner, P., Bone, D. H., and
Goosen, M. F. A., Appl. Microbiol. Biotechnol., 32, 249
(1989); Godwin, G., Belisle, B., De Giovanni, A., Kohler, J.,
Gong, T., and Wojchowski, D., In Vitro, 25, 17a (1989)].
Individual Sf9 cells have diameters from i0 to 20 Bm and can
be maintained by following standard published protocols known
to those skilled in the art of animal cell culture with the
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following exceptions that are distinctly different from
typical animal culture protocols: they grow optimally at 27
rather than 37 °C, external CO 2 is not required for growth
since the cells generate significant quantities of the gas as
a metabolic end product, and the pH for growth media is 6.2
instead of 7.4 because the cells raise pH as they grow rather
than lower it [Fraser, M. J., In Vitro Cell. Dev. Biol., 25,
225 (1989); Godwin, G., Belisle, B., De Giovanni, A., Kohler,
J., Gong, T., and Wojchowski, D., In Vitro, 25, 17a (1989)].
Sf9 shows great promise as an animal-cell host for the
production of recombinant proteins. One of the reasons is the
ease at which proteins can be cloned, expressed and purified
relative to vertebrate animal cells. Sf9 more readily accepts
foreign genes coding for recombinant proteins than many
vertebrate animal cells because it is very receptive to viral
infection and replication [Bishop, D. H. L. and Possee, R. D.,
Adv. Gene Technol., i, 55, (1990)]. Expression levels or
recombinant proteins are extremely high in Sf9 and can
approach 500mg/liter [Webb, N. R. and Summers, M. D.,
Technique, 2, 173 (1990)]. The cell line performs a number of
key post-translational modifications; however, they are not
identical to those in vertebnates and, therefore, may alter
protein function [Fraser, M. J., In Vitro Cell. Dev. Biol.,
25, 225 (1989)]. Despite this, the majority of recombinant
proteins that undergo post-translational modification in
insect cells are immunologically and functionally similar to
their native counterparts [Fraser, M. J., In Vitro Cell. Dev.
Biol., 25, 225 (1989)]. In contrast to animal cell culture,
Sf9 facilitates protein purification by expressing relatively
low levels of proteases and having a high ratio of recombinant
to native protein expression [Goswami, B. B. and Glazer, R. O.
BioTechniques, I0, 626 (1991)].
There has been an explosive growth in the number of
proteins that have been expressed in Sf9 with less than i0 by
9
PATENT
5
I0
15
2O
25
3O
1985 to over i00 by 1990. These include @-interferon [Smith,
G. E., Summers, M. D., and Fraser, M. J., Mol. Cell. Biol., 3,
2156 (1983)], interleukin-2 [Smith, G. E., Ju, G., Ericson, B.
L., Moschera, J., Lahm, H., Chizzonite, R., and Summers, M.
D., Proc. Nat. Acad. sci. USA, 82, 8404 (1985)], chimeric
plasminogen activators [Devlin, J. J., Devlin, P. E., Clark,
R., O'Rourke, E. C., Levenson, C., and Mark, D. F.,
Bio/Technology, 7, 286 (1989)] and macrophage colony
stimulating factor [Chiou, C. J., and Wu, M. C., FEB, 259, 249
(1990)] to name a few.
Baculoviruses serve as expression systems for the
production of recombinant proteins in insect cells. These
viruses are pathogenic towards specific species of insects,
causing cell lysis [Webb, N. R. and Summers, M. D., Technique,
2, 173 (1990)]. They are, and have been, a natural part of
the ecosystem where they control the population size of their
hosts [Miltenburger, H. G. and Kreig, A., Advances in
Biotechnological Processes, 3, 291 (1984)]. Some 300 species
of baculovirus have been isolated. They are nonhazardous to
humans, other vertebrates and indeed most invertebrates.
After acute exposure of baculovirus from Autographa
californica, Mamestra brassicae and Cydiapomonella, NMRI mice
and Chinese hamsters had no chromosomal aberrations or health
disturbances [Miltenburger, H. G. and Kreig, A., Advances in
Biotechnological Processes, 3, 291 (1984)]. Similarly,
physical examinations and laboratory tests failed to detect
any abnormalities in humans given various baculoviruses orally
[Heimpel, A. M. and Buchanan, L. K., J. Invertebr. Pathol, 9,
55 (1967)].
Baculoviruses are desirable alternatives to conventional
chemical insecticides for agricultural pest control because of
their selective pathogenicity towards targeted insects, non-
pathogenicity towards vertebrates and compatibility with the
ecosystem. At least three baculoviruses have been registered
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by the Environmental Protection Agency for commercial
distribution as insecticides: the baculoviruses of Heliothis
zea, Orgyia pseudotsugata and Lymantria dispar [Miltenburger,
H. G. and Kreig, A., Advances in Biotechnological Processes,
3, 291 (1984)]. Baculovirus has been successfully tested to
control insect populations in Sweden, the Soviet Union, Italy,
Canada and the United States [Miltenburger, H. G. and Kreig,
A., Advances in Biotechnological Processes, 3, 291 (1984)].
At present, chemical insecticides are the primary means of
controlling pest populations. Their use, however, is facing
growing opposition--they pollute the environment, and insects
may become resistant to their effects. It is estimated that
30% of the agricultural pests in the Western Hemisphere can be
controlled by insect viruses [Falcon, L. A., in Viral
Pesticides: Present Knowledge and Potential Effects on Public
and Environmental Health, Summers, M. D. and Kawanishi, C. Y.,
eds. (Health Effects Research Laboratory, Office of Health and
Ecological Effects, U.S. Environmental Protection Agency,
Research Triangle Park, NC, 1978), p.ll]. This is a
significant figure. Substituting baculovirus for its chemical
counterpart in these cases could substantially reduce the
total amount of chemical insecticides used in the environment.
Recombinant protein expression is achieved by cloning the
desired gene into baculovirus at the site of the wild-type
polyhedrin gene [Webb, N. R. and Summers, M. D., Technique, 2,
173 (1990); Bishop, D. H. L. and Possee, R. D., Adv. Gene
Technol., 1, 55, (1990)]. The polyhedrin gene is nonessential
for infection or replication of baculovirus. It is the
principle component of a protein coat in occlusions which
encapsulate virus particles. When a deletion or insertion is
made in the polyhedrin gene, occlusions fail to form.
Occlusion negative viruses produce distinct morphological
differences from the wild-type virus. These differences
enable a researcher to identify and purify a recombinant
ii
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virus. In baculovirus, the cloned gene is under the control
of the polyhedrin promoter, a strong promoter which is
responsible for the high expression levels of recombinant
protein that characterize this system. Expression of
recombinant protein typically begins within 24 hours after
viral infection and terminates after 72 hours when the Sf9
culture has lysed.
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SUMMARY OF THE INVENTION
Insect cells have shown promise for recombinant protein
product. This is dependent upon a large scale production
system that provides the proper environment. The subject of
this invention is recombinant protein production using a
unique process for insect cell culture. Higher expression
rates and greater yields that can be realized with the new
production systems will increase the variety of protein
products and lower their cost to consumers. This can result
in, for example, new biotherapies to treat disease, more
sensitive diagnostic agents that will detect life-threatening
illness sooner, and natural insecticides that have greater
species specificity. Because recombinant proteins are germane
to many disciplines, this invention will have a fundamental
impact in many areas of investigation. This invention can be
used for commercial protein production.
A new process system has been discovered for in vitro
cultivation of shear-sensitive, invertebrate cells,
specifically insect cells, and for the production of
recombinant proteins from these cells. Insect cells were
cultivated in a bioreactor which is a horizontally rotating
culture vessel designed to create low shear by modulating the
rotation, preferably in a bioreactor called the High Aspect
Ratio Vessel (HARV) described in the published patent
application by the National Aeronautics and Space
12
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Administration in the Scientific and Technical Aerospace
Reports Volume 29/Number 9, May 8, 1991, ACC NOS. N91-17531,
U.S. Serial No. 625,345 now U.S. Patent No. 5,153,131,
entitled "A Culture Vessel With Large Perfusion Area to Volume
Ratio," invented by David A. Wolf, Clarence F. Sams and Ray P.
Schwarz and filed on December Ii, 1990 and issued October 6,
1992, which patent is incorporated by reference in its
entirety in this specification.
The insect cells were used for production of recombinant
polypeptides herein defined as a type of polypeptide, protein
or virus. For the purposes of this invention the terms
polypeptide and protein are not intended to limit the scope of
production of any selected amino acid sequence. The insect
cells are selected and transformed to include a selected DNA
sequence encoding the desired polypeptide product' The cells
are then cultured in the HARV which is a horizontally rotating
culture vessel designed to create low shear conditions by
modulating the rotation. The insect cells cultured by this
process recombinantly produce the selected polypeptide which
can then be collected and purified. A preferred method for
transformation of the insect cells utilizes an insect
pathogenic virus, specifically a baculovirus, cloned with the
selected DNA sequence. If desired, selected DNA sequences can
be used in the transformation process that promote the
expression of the DNA sequence encoding the polypeptide.
Selective initiation methods for producing the recombinant
polypeptide may also be utilized. For instance, a regulation
sequence that can turn on protein production by exposure to
certain conditions or in the presence of certain compounds can
be included in the DNA sequence used to transform the insect
cells. In an alternative process, the insect cells are used
as hosts for virus production. The virus may be wild type or
transformed. Lepidoptera cells are a preferred cell for
transformation, and other insect cells that can be cultured by
13
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the process of this invention may be used.
may be cultured in a HARV or other
transformation.
The insect cells cultured by the
The insect cells
vessel prior to
process of this
invention produce a cell line with characteristic metabolism
regardless of the genetic transformation to produce a new cell
line. The metabolically transformed Lepidoptera cell line of
this invention has been designated RES. Specifically, both
non-infected and baculovirus-infected RES utilize an alternate
metabolic pathway as compared to their Sf9 counterparts
characterized by pH change, glucose and amino acid
consumption, and lactic acid production. Transformations can
be viral or metabolic or both.
An alternative process of this invention utilizes an
insect pathogenic virus to produce recombinantly the selected
polypeptide using the insect cells as a host. The preferred
virus is a baculovirus. The virus is prepared to include the
incorporation of the selected DNA sequence encoding the
polypeptide. Other DNA sequences to promote or enhance the
expression and production of the polypeptide may also be
included in the incorporated DNA sequence. The insect cells
are cultured as described herein and the selected virus is
transferred into the culture vessel inoculating the insect
cells. The virus infects the insect cells and uses the insect
cells as a host to replicate and produce the encoded
polypeptide. The polypeptide may be collected and purified as
desired.
In the preferred process using the HARV, insect cells
were grown in a liquid medium suspension without support
matrices such as microcarrier beads. In this environment, the
cells aggregated into 3 mm spherical structures that retained
high viability in excess of 95%. Maximum cell densities in
the HARV range from 5 x 106 to 1 x 107 viable cells/ml. In
contrast, insect cells remain as a single-cell suspension when
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cultivated with conventional animal-cell bioreactors such as
stirred tanks. Moreover, maximum cell densities ranged
between 1.5 x 106 to 4 x 106 total cells/ml and are on a total
rather than a viable cell basis. [Murhammer, D. W. and
Goochee, C. F., Biotechnol. Prog., 6, 391 (1990)]. Similar
values were reported by Ogonah et al. [1991]. [Ogonah, O.,
Shuler, M. L., and Granados, R. R., Biotechnol. Lett., 13, 265
(1991) ] .
Further distinctions between the process of this
invention and conventional cultivation were observed after
insect cells were infected with recombinant baculovirus coding
for the protein _-galactosidase (_-gal). Using the process of
the present invention, the cultures infected at a
concentration of 1.3 x 106 viable cells/ml with a multiplicity
of infection (MOI) of I0 continued to grow for a period of 35
hours after infection to 1.7 x 106 while retaining a viability
that exceeded 90%. Under the same infection conditions,
conventional cultivation in shaker flasks resulted in a loss
in viable cell concentration within 24 hours after infection.
In fact, viable cell concentration remained higher in the HARV
throughout the 180 hours of cultivation by approximately a
factor of 2 or greater. These higher concentrations can
result in a greater yield of baculovirus and recombinant
protein from the HARV culture. Moreover, these results are
illustrative of alternate metabolic pathway usage. Not only
does this represent a new process for expressing protein, but
enables the production of pathogenic virus for use as an
insecticide.
Production of recombinant @-gal using the present
invention surpassed that achieved in shaker flasks. For the
infection conditions described in the previous paragraph, the
amount of @-gal present was greater by a factor of 2 to 7
during cultivation, resulting in a total yield of protein that
ranged from 8 to 33 units of _-gal/ml medium. A unit of @-gal
15
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is defined as the amount of the enzyme required to hydrolyze
1.0 _mole/min o-nitrophenyl-@-D-galactopyranoside (ONPG) at pH
7.3 and 37 °C.
DETAILED DESCRIPTION OF THE INVENTION
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Insect cells for in vitro cultivation have been produced
and several cell lines are commercially available. This
process includes using insect cells capable of culture as
described herein. The preferred cell line is Lepidoptera Sf9
cells. Other cell lines include Lepidopteran cell line High
Five and cabbage looper "Trichoplusia ni" both available from
Invitrogen Corporation. Sf9 insect cells from Invitrogen
Corporation are the preferred cell line and were cultivated in
the bioreactor freely suspended in serum-free EX-CELL 401
Medium purchased from JRH Biosciences and maintained at 27"C.
The preferred bioreactor is the HARV as described above. The
metabolically transformed cell line RES derived from the Sf9
cells was cultivated in the HARV using the process of this
invention. To inoculate the HARV, it was first half-filled
with medium to act as a cushion for the suspended Sf9 cells as
they were pipetted into the vessel. The volume of suspended
cells necessary for the desired cell density of 1 x 106
cells/ml was added to this medium. Additional medium was used
to fill the vessel. Two 5-ml syringes half-filled with medium
were attached to the small ports and manipulated to remove all
air bubbles from the vessel. One syringe was removed, the
open small port was capped, and one syringe remained attached
for pressure equalization. The vessel was screwed into its
base. The initial rotation speed was set at ii or 12 rpm,
with adjustments made to modulate the rotation to create and
maintain low shear conditions while maintaining cellular
suspension.
The pH was monitored to determine the frequency with
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which to replace conditioned media. As fresh media has a pH
of 6.4, the objective was to maintain the pH of the cultures
as close to 6.4 as possible so as not to deplete the nutrients
necessary for normal cell growth. At best, the cultures could
be maintained within a pH range of 6.1 to 6.3. When the pH
dropped to 6.1, the culture received a 20% change of medium.
The vessel rotation was stopped, and the culture remained
stationary for about 5 minutes until the medium near the top
port had clarified. Conditioned medium (i0 ml) was removed
through the top port and replaced with fresh medium. Air
bubbles were eliminated from the vessel, and rotation was
resumed.
Cell density and viability of the HARV cultures were
checked by staining a sample with trypan blue and examining
with a hemocytometer under a microscope at low magnification.
Glucose concentration of the cultures was monitored with a
Yellow springs Instruments (YSI) Model 27 Industrial Analyzer
equipped with a glucose membrane kit (YSI 2365). The analyzer
measured the amount of hydrogen peroxide produced in the
enzymatic conversion of glucose (with glucose oxidase acting
as the enzyme). The glucose concentration was maintained
between 200 and i00 mg/dl. When it dropped to I00 mg/dl, the
culture received a change of medium sufficient to increase the
concentration to 200 mg/dl. The amount of time necessary for
the cultures to deplete the concentration from 200 to i00
mg/dl was noted, and the rate of glucose metabolization was
determined.
RES cells cultivated in the HARV in this manner,
aggregated into spherical structures as large as 3 mm in
diameter which readily dissociate with minimal agitation. In
contrast, insect cells remain as a single-cell suspension when
cultivated with conventional animal-cell bioreactors such as
stirred tanks. Aggregated cultures retained high viability in
the HARV - in excess of 95%. Maximum cell densities in the
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HARV range from 5 x 106 to 1 x 107 viable cells/ml. These
values are higher and unanticipated in view of the reported
findings by Murhammer and Goochee for a sparged bioreactors of
the stirred-tank design and for airlift bioreactors.
[Murhammer, D. W. and Goochee, C. F., Biotechnol. Prog., 6,
391 (1990)]. In these cases, maximum cell densities ranged
between 1.5 and 106 to 4 x 106 total cells/ml and are on a
total rather than a viable cell basis. Similar values were
reported by Ogonah et al. [Ogonah, O., Shuler, M. L., and
Granados, R. R., Biotechnol. Lett., 13, 265 (1991)].
Conditioned medium in the HARV was also analyzed for
amino acid, ammonia and lactic acid content during
cultivation. A Beckman 6300 High Performance Amino Acid
Analyzer containing a i0 cm lithium high performance column
(Beckman 338051) measured the concentration of amino acids in
the medium with ninhydrin detection (Beckman application notes
A6300-AN-003, October 1985). Ammonia concentration was
determined from a spectrophotometric assay monitoring the
reductive amination of 2-oxoglutarate to glutamate in the
presence of glutamate dehydrogenase (sigma kit 171) on a
Beckman Synchron CX5 Clinical Analyzer. A second
spectrophotometric assay measured lactic acid concentration
from the conversion of lactate to pyruvate catalyzed by
lactate dehydrogenase (Sigma kit 826) on a Cobas MIRA
Chemistry System (Roche Diagnostic System).
The RES cells cultured in the HARV have a different type
of metabolism from the parent cell line, Sf9 cells cultured by
methods typically used such as shaker cultures. The low-
turbulence, low-shear environment of the HARV has a profound
effect on cell metabolism relative to that obtained in shakers
cultures. In shaker cultures, cells are mixed by orbital-bed
rotation rather than impeller mixing, making the shaker
culture one of the most gentle forms of conventional
cultivation for suspension cells. Glucose utilization is less
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in the HARV; cells consume on average 6 x 10 -6 mg/dl cell hr
in the HARV as compared to 3 x 10 -5 mg/dl cell hr in shaker
cultures. The pH profile follows a different trend; pH
changes more rapidly in the HARV at a rate of 2 x 10 -7 A pH
units/cell hr as compared with 4 x 10 -8 A pH units/cell hr in
shaker cultures. The Sf9 insect cell line with altered
metabolism has been designed as cell line RES and is the
preferred cell line for recombinant polypeptide production and
viral production.
For viral infection, RES cells were exposed to a
recombinant Autograhpa californica baculovirus from Invitrogen
Corporation. Specifically, the HARV was seeded with Sf9 cells
at a density of 0.7 x 106 viable cells/ml. The cultivation
protocol was followed until the cells saw a normal doubling
time (the cell density increased from 0.7 x 106 to 1.3 x 106
in approximately 24 hours), confirming the onset of
exponential growth. The reactor was inoculated with virus at
the onset of exponential growth in order to maximize virus
yield. For the inoculation, 20% of the conditioned medium was
removed and replaced with an equal volume of fresh medium
containing the calculated amount of virus for an MOI
(multiplicity of infection) of i0. Thereafter, the infected
culture received a 10-20% medium change as needed to maintain
the pH between 6.1 and 6.3 and the glucose concentration
between I00 and 200 mg/dl. The cell density and viability
were checked daily, as the baculovirus is pathogenic towards
Sf9 cells, causing eventual cell death and lysing. When the
number of viable cells dropped to 10% of the total cell
number, a maximum virus yield was reached, and the experiment
was terminated. This transforms the insect cell line to
include a DNA sequence encoding for a selected polypeptide.
In this case the baculovirus and @-gal were used as a model
system. The model system was then cultured in a horizontally
rotating vessel modulated to create low shear conditions which
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facilitated recombinant polypeptide production.
Infected cultures were maintained in the HARV and in
spinner flasks for 180 hours after the initial inoculation.
During this time, there were profound differences in the
response of the insect cells to virus infection with these two
types of bioreactor. Both the HARV and spinner-flask cultures
were infected at a concentration of 1.3 x 106 viable cells/ml
with a MOI of i0 as described above. The HARV culture grew
for an unexpected period of 35 hours after infection to 1.7 x
106 viable cells/ml while retaining a viability that exceeded
90%. After this initial period of growth, both viability and
cell concentration dropped until they reached 8.2% and 1.2 x
105 viable cells/ml, respectively, at the end of the
experiment. In contrast, shaker cultures experienced a
continuous reduction in viability and cell concentration
throughout the experiment until these values reached 6.4% and
4.0 x 104 viable cells/ml. It was discovered that over the
entire 180 hours of cultivation, viable cell concentration
remained higher in the HARV by approximately a factor of 2 or
greater. The improvement is attributed to the unexpected
altered metabolism. Metabolism is focused on viral products
and not diverted to the repair damage results from detrimental
shear forces. These higher concentrations can result in a
greater yield of baculovirus and recombinant proteins from the
HARV culture.
After infection with baculovirus, RES cells in the HARV
retain a distinctive metabolic profile that distinguish them
from Sf9 cells. Glucose utilization and change in the pH of
conditioned medium are examples of this behavior. The pH of
both shaker and HARV cultures changed at approximately the
same rate during the initial 24 hours of infection: 3.1 x 10 -9
A pH units/cell hr in shaker flasks and 2.5 x 10 -9 A pH
units/cell hr in the HARV. For the remainder of the
experiment in shaker flasks, pH changed at a slightly higher
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rate of 4.7 x 10 -9 A pH units/cell hr after 60 hours of
infection and 6.0 x 10 -9 _ pH units/cell hr after 180 hours.
Rather than an increase, RES cultures in the HARV experience
a decrease in the rate of pH change as infection progressed to
0.85 x 10 -9 A pH units/cell hr after 60 hours and 0.29 x 10 -9
A pH units/cell hr after 180 hours. There are analogous data
for glucose. Glucose utilization in the HARV was less than in
shaker flasks. In the HARV, the rate at which glucose was
consumed was reduced from a value of 1.4 x 10 -7 mg/dl cell hr
after 35 hours of infection to 0.67 x 10 -7 mg/dl cell hr after
an additional 54 hours. For shaker flasks, the initial rate
was higher at 7.7 x 10 -7 mg/dl cell hr after 35 hours. This
rate also was lowered as the infection progressed but only to
2.0 x 10 -7 mg/dl cell hr.
To determine virus production as a function of time,
infected cultures were titered daily using the following blue
plaque assay from Invitrogen Corporation. Sf9 cells were
seeded into four 60 x 15 mm animal cell culture plates at 80%
confluency and allowed to attach for 30 to 45 minutes. The
conditioned medium was removed from the attached cells after
rocking the plates from side to side to pick up dead cells and
debris. Each plate was washed with 1 ml fresh medium to
remove any remaining debris, being careful not to pipet across
the cell layer as this would have dislodged the attached
cells.
Ten-fold dilutions of the virus inoculum were prepared.
For the first dilution (10-1), 0.ii ml of cell-free virus
sample was added to 0.99 ml of fresh medium. For the second
dilution (10-2), 0.ii ml of the first dilution was added to
0.99 ml fresh medium. This process was continued for
subsequent dilutions through 10 -8 •
The virus dilutions were added to the prepared plates.
One milliliter of a dilution was uniformly spread on each
plate, making four plates, one each of 10 -8 , 10 -7 , 10 -6 , and
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10-5 dilutions. The virus was allowed to infect the cells for
one hour. After one hour, the virus inoculum was drawn off,
leaving the attached, infected cells on the plate.
The agarose was prepared during the hour in which the
virus was infecting the cells. For four plates, 0.38 g
agarose was added to 12.5 ml Millipore water and autoclaved at
120°C for 15 minutes. Once autoclaved, the agarose was
maintained at 40°C. The 2X Hink's TNM-FH Medium (containing
fetal bovine serum to compensate for the toxicity of the
agarose) was warmed to 40°C. Three milligrams of X-gal were
mixed with 0.15 ml DMSO. To the warmed agarose, 0.125 ml of
the X-gaI-DMSO mixture and 12.5 ml of the 2X medium were
added. Each plate received 5 ml of the agarose mixture, being
careful not to dislodge the attached cells by pipetting across
the cell layer. Once the agarose had solidified, the plates
were stored in a plastic bag with a damp paper towel to create
a humid environment to prevent cracking of the agarose.
By the tenth day, blue recombinant plaques were visible.
The virus titer was determined by taking the number of plaques
on a plate and dividing by the dilution factor of that plate.
_-Galactosidase (_-Gal) served as a model protein to
investigate recombinant protein production from baculovirus-
infected insect cells in the HARV and baculovirus served as a
model virus for pathogen production. This protein is
frequently used in Sf9 studies since it is readily available
and can be easily assayed. A mutant form of the baculovirus
A. californica (or a pathogen type in an alternate embodiment
for virus production) containing the gene coding for _-Gal was
used as a cloning vector to introduce and express the @-Gal
gene in Sf9 cells. As the virus replicates, the _-Gal gene is
expressed along with native viral proteins. The effect that
the HARV has on recombinant @-Gal production is two fold; it
enhances both total and intrinsic production. Because the
HARV cultures insect cells to larger cell densities than other
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conventional bioreactors, the overall production of the HARV
culture on a per volume basis is larger than in conventional
systems. On an intrinsic level, the HARV also raises the rate
of recombinant protein synthesis through viral infectivity
and/or cell metabolism. As for the former, the low-turbulence
environment of the HARV facilitates adherence of viral
particle to the cell surface. As for the latter, the changes
that the HARV causes in cell metabolism may result in an
increase in gene transcription, protein translation, post-
translational processes and protein secretion from the cell.
The level of intracellular and extracellular recombinant
@-galactosidase expression was measured with a
spectrophotometric assay on a Thermomax microplate reader.
The process for collecting the recombinantly produced
polypeptide included pipetting spent cell culture media from
the culture vessel into a test tube. The contents of the test
tube were then assayed for the amount of @-gal present in the
spent media. In an alternate embodiment, spent cell culture
media with suspended cells was pipetted into a test tube. The
test tube was centrifuged at 500 x g to pellet cells
containing recombinantly produced polypeptide. The
supernatent was removed and the cells were lysated by standard
sonication or detergent preparations. The lysate was
suspended in buffer and assayed for recombinantly produced
polypeptide, for example @-gal. In an alternate embodiment
the spent cell culture media containing recombinantly produced
polypeptide or the lysate containing recombinantly produced
polypeptide can be purified by standard molecular weight
exclusion filtration, by column chromatography, by
immunoprecipitation/absorption, or by centrifugation
techniques known in the art for the specific recombinantly
produced polypeptide. Specifically, the assay determined the
amount of _-gal present based on the enzymatic conversion of
o-nitrophenyl-@-D-galactopyranoside (ONPG) to o-nitrophenol
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and galactose. It measured the steady-state rate of ONPG
consumption at 410 nm, 37°C, and pH 7.3 in 250 _i of solution
of 0.08 M NaPO4, 0.ii M 2-mercaptoethanol, 0.001 M MgCI2-6H20,
and 0.002 M ONPG and 8 _i of enzymatic @-gal sample. At a
wavelength of 410 nm, the molar extinction coefficient for
ONPG is 3.5 mmole-lcm -1. Doubling the amount of @-gal present
did not affect measurements of rate per unit amount of enzyme.
In the HARV, _-gal began to accumulate intracellularly 35
hours after the initial infection. Extracellular expression
of the recombinant protein began 12 hours later. Using the
infection protocol described above, the maximum @-gal
concentration achieved in the HARV was 29 U/ml medium
intracellularly and 7 U/ml extracellularly after 105 and 140
hours of infection, respectively. By definition, a unit of _-
gal hydrolyzes 1.0 _mole/min ONPG at pH 7.3 and 37°C. The
maximum yield of @-gal (i.e., the combination of its
intracellular and extracellular concentration) was 33 U/m1
also at 105 hours. From 105 to 180 hours when the experiment
was terminated, the @-gal yield dropped to 9 U/m1 possibly as
the result of denaturation or proteolytic activity. For
comparison, the maximum intracellular and extracellular
concentrations of @-gal in shaker cultures infected under
identical conditions were 3.7 U/ml at 95 hours and 3.2 U/ml at
155 hours, respectively. The maximum yield occurred at 95
hours and was 5 U/ml. As in the HARV, the yield dropped to
4.3 U/ml as the experiment progressed to 180 hours. During
the course of the experiment it was discovered that the yield
of _-gal was greater in the HARV by a factor ranging between
2 to 7.
The disclosure herein will be understood by those skilled
in the art. It is not intended to limit the claimed invention
to those processes and products expressly discussed.
Alternative methods to practice this invention will be
recognized by those skilled in the art.
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ABSTRACT
A process has been developed for recombinant production
of selected polypeptides using transformed insect cells
cultured in a horizontally rotating culture vessel modulated
to create low shear conditions. A metabolically transformed
insect cell line is produced using the culture procedure
regardless of genetic transformation. The recombinant
polypeptide can be produced by an alternative process using
the cultured insect cells as host for a virus encoding the
described polypeptide such as baculovirus. The insect cells
can also be a host for viral production.
